Correlation between Apolipoprotein B/Apolipoprotein A-I Ratio with Atherogenic Index of Plasma among Acute Myocardial Infarction Patients

Winardi Emmanuel Setiawan, Anggoro Budi Hartopo, Royhan Rozqie


BACKGROUND: Acute myocardial infarction (AMI) is the most common cause of death in the world. One preventive attempt to reduce AMI is early detection of blood lipid profile. A simple method of lipid profile assessment is the measurement of atherogenic index of plasma (AIP), meanwhile more accurate method of lipid profile assessment is the measurement of apolipoprotein B/apolipoprotien A-I (ApoB/ApoAI) ratio. However, whether both measurements are interchangeable is need to be investigated. This study aims to investigate the correlation between AIP value and ApoB/ApoAI ratio in patients with AMI.

METHODS: The study design was cross-sectional study. The blood samples of consecutively enrolled AMI patients had been selected after inclusion and exclusion criteria. The blood samples were taken within 24 hours of patient admission to the hospital. The blood concentration of high-density lipoprotein (HDL) and triglycerides (TG) were measured using turbidimetric method. The AIP was calculated as logarithmic of TG/HDL ratio (log10.[TG:HDL]) The concentration of ApoB and ApoAI were measured using immunoturbidimetric method. The correlation between these measurements was analyzed with Pearson correlation test.

RESULTS: The blood samples of 76 subjects were collected and analyzed. The subjects were dominated by male (n=67, 88%) and those whose age ≥55 years old (n=54, 71%). The mean ApoB value was 88.66 mg/dL and ApoAI was 97.39 mg/dL. The AIP value was 0.05. The Pearson correlation test between AIP and ApoB/ApoAI ratio showed a significant positive correlation with the strength of correlation was moderate (r=0.51, p-value<0.01).

CONCLUSION: There was a significantly positive and moderate correlation between AIP value and ApoB/ApoAI ratio in acute myocardial infarction patients.

KEYWORDS: atherogenic index of plasma, acute myocardial infarction, apolipoprotein B/apolipoprotein A-I ratio

Full Text:



World Health Organization [Internet]. Cardiovascular diseases (CVDs) [cited 2015 Apr 27]. Available from:

Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan Republik Indonesia. Riset Kesehatan Dasar (RISKESDAS) Tahun 2007. Jakarta: Kementrian Kesehatan RI; 2007, article.

Willerson JT, Cohn JN, Wellens HJJ, Holmes DR Jr. Cardiovascular Medicine. 3rd ed. London: Springer; 2007, NLMID.

Faqih DM, Paranadipa M, Trisna DV, Waluyo DA, Herqutanto, Ekayanti F, et al. Panduan Praktik Klinis Bagi Dokter di Fasilitas Pelayanan Kesehatan Primer. 1st edition. Jakarta: Ikatan Dokter Indonesia; 2013.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97, CrossRef.

Baynes JW, Dominiczak MH. Medical Biochemistry. 2nd edition. London: Elsevier; 2007.

Dobiasova M, Frohlich J. The new atherogenic plasma index reflects the triglyceride andHDL-cholesterol ratio, the lipoprotein particle size and the cholesterolesterification rate: changes during lipanor therapy. Vnitr Lek. 2000; 46: 152-56, PMID.

Lee DM, Alaupovic P. Composition and concentration of apolipoproteins in very-low- and low-density lipoproteins of normal human plasma. Atherosclerosis. 1974; 19: 501-20, PMID.

Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 1992; 69: 1015-21, CrossRef.

Kaneva AM, Potolitsyna NN, Bojko ER, Odland JØ. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity. Dis Markers. 2015; 2015: 591454, CrossRef.

Dobiasova M. AIP--Atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006; 52: 64-71, PMID.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS Study): a prospective study. Lancet. 2001; 358: 2026-33, CrossRef.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-52, CrossRef.

Hartopo AB, Gharini PPR, Hariawan H, Puspitawati I. Lipid Terogenik Plasma Sebagai Prediktor Kejadian Buruk Kardiovaskular Selama Perawatan Penderita Sindroma Koroner Akut [Laporan Penelitian]. Yogyakarta: Fakultas Kedokteran Universitas Gadjah Mada; 2013.

Saputri D, Hariawan H, Irawan B. High Apo B/Apo A-1 serum ratio as a predictor of in-hospital major adverse cardiovascular events in acute coronary syndrome patients. Acta Cardiol Indones. 2015; 1: 52-9, article.

Crawford MH. Current Diagnosis & Treatment: Cardiology. 3rd ed. USA: McGraw-Hill Companies; 2009.

Fuster V, Walsh RA, O'Rourke RA, Poole-Wilson P. Hurst’s the Heart. 13th ed. USA: McGraw-Hill Companies; 2011, NLMID.

Khazaal MS. Atherogenic index of plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios). Karbala J Med. 2013; 6: 1506-13, article.

McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEARTstudy): a case–control study. Lancet. 2008; 72: 224-33, CrossRef.


Indexed by:






The Prodia Education and Research Institute